BCL2L1 and Thrombocytopenia: For example, navitoclax and ABT-737 demonstrate robust senolytic activity in certain cell populations but cause thrombocytopenia due to BCL-XL dependence in platelets, highlighting the risk of unintended toxicity in non-senescent cells [35,54].